Liminal BioSciences Inc. - LMNL STOCK NEWS

Liminal BioSciences Inc. (Nasdaq: LMNL) will present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, from 3:30 to 3:50 PM (EDT). The live webcast will be available on the company's website, with an archived replay for at least 7 days.

Focused on novel treatments for fibrotic diseases, Liminal is advancing their lead candidate, fezagepras (PBI-4050), into a Phase 1 trial in 2H-2020. Additionally, they have resubmitted a BLA for Ryplazim® to the FDA for congenital plasminogen deficiency.

Liminal BioSciences Inc. (Nasdaq: LMNL) has resubmitted its Biologics License Application (BLA) for Ryplazim^® (plasminogen), aiming for FDA approval as the first treatment for congenital plasminogen deficiency (C-PLGD). Results from a phase 2/3 study showed all 15 patients achieved increase in plasminogen activity and complete healing of lesions within 48 weeks. Pending the FDA's response, the company may obtain a priority review voucher. C-PLGD currently lacks approved therapies.

Liminal BioSciences Inc. (Nasdaq: LMNL) announced the appointment of Alek Krstajic and Eugene Siklos to its Board of Directors, effective immediately, to fill vacancies from resignations. Krstajic, former CEO of Wind Mobile, brings extensive leadership experience, while Siklos, President of ThomVest Asset Management, offers a strong financial background. CEO Kenneth Galbraith expressed confidence in their contributions as the company prepares for a BLA filing for Ryplazim this quarter, with potential commercialization in 2021, marking significant growth prospects for the company.

Liminal BioSciences (Nasdaq: LMNL) announced its Q2 2020 results, showing a significant reduction in net loss from continuing operations by approximately 80% year-over-year, totaling $27.8 million. The company has joined the CoVIg-19 Plasma Alliance and acquired the OXER1 R&D program. It voluntarily delisted from the Toronto Stock Exchange effective August 5, 2020, as the majority of trading has shifted to Nasdaq. Key milestones include a planned BLA resubmission for Ryplazim® in Q3 2020 and the initiation of a Phase 1 clinical study for fezagepras in H2 2020.

Liminal BioSciences Inc. (Nasdaq: LMNL), a clinical-stage biopharmaceutical company, announced that CEO Kenneth Galbraith will present at the Canaccord 40th Annual Growth Conference on August 13, 2020, from 2:00 PM to 2:25 PM EDT. The presentation will be accessible via live webcast on the company's website, with an archived replay available for at least seven days post-event.

The company is focused on developing treatments for fibrosis-related diseases and plans to start additional Phase 1 clinical trials for its lead drug candidate, fezagepras, in the second half of 2020.

Liminal BioSciences Inc. (NASDAQ: LMNL) has applied for a voluntary delisting of its common shares from the Toronto Stock Exchange (TSX) effective August 5, 2020, due to increased trading activity on NASDAQ since late 2019. The dual listing's financial and administrative costs were evaluated, leading to this decision. There is no expected impact on ongoing operations. Shareholders in Canadian brokerages are advised to check trading options on NASDAQ. The company focuses on biopharmaceutical solutions for fibrosis and has a lead candidate, fezagepras, entering clinical trials in late 2020.

Liminal BioSciences (Nasdaq: LMNL) has acquired Fairhaven Pharmaceuticals, enhancing its R&D capabilities with a preclinical program focused on eosinophil-driven diseases. The acquisition, totaling C$8 million, includes an initial share issuance of C$3.6 million. The Fairhaven R&D Program aims to develop small molecule antagonists targeting eosinophil chemoattractants, addressing a significant unmet medical need in therapies for respiratory and gastrointestinal diseases. With a solid pipeline, Liminal aims to leverage its expertise in GPCRs to advance these promising therapies.

Liminal BioSciences Inc. (NASDAQ: LMNL) announced on July 2, 2020, that its subsidiary, Prometic Plasma Resources, has joined the CoVIg-19 Plasma Alliance. This collaboration aims to expedite the development of a new therapy for COVID-19 by leveraging the expertise of leading plasma-derived therapeutic companies. The Alliance seeks to collect convalescent plasma for creating a potential treatment for COVID-19. Liminal BioSciences is focused on developing novel therapies for fibrotic diseases and is advancing its lead product candidate, Ryplazim, with a BLA resubmission expected in Q3-2020.

Liminal BioSciences (NASDAQ: LMNL) announced on June 30, 2020, that its subsidiary, Prometic Plasma Resources, has initiated the collection of convalescent plasma from COVID-19 survivors. This effort aims to assist in the development of hyperimmune immunoglobulin therapies for COVID-19 patients. CEO Kenneth Galbraith highlighted the importance of this initiative, calling for recovered individuals to donate plasma. The company also plans to resubmit a Biologics License Application (BLA) for its lead product, Ryplazim, in Q3 2020, targeting congenital plasminogen deficiency.